SCHEMBL4920260

SCHEMBL4920260

CCOC(=O)c1ccc(NC(=O)Nc2ccc(-c3csnn3)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.65
TP53 P04637 1/20 0.65
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
TRPV1 Q8NER1 2/20 0.57
CASP3 P42574 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
LMNA P02545 1/20 0.55
PKM P14618 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 2/20 0.52
MAPK1 P28482 2/20 0.52
ALDH1A1 P00352 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MDM2 Q00987 1/20 0.51
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911091 0.78 MAPT (0.60) MAPTKMT2AMEN1TRPV1CASP3
SCHEMBL28750524 0.78 MAPT (0.58) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL4911322 0.76 NPC1 (0.59) MAPTKMT2AMEN1TRPV1CASP3
SCHEMBL4113307 0.76 MAPT (0.77) MAPTTP53KMT2AMEN1TRPV1
SCHEMBL4112088 0.75 KMT2A (0.75) MAPTTP53KMT2AMEN1TRPV1
SCHEMBL4922844 0.75 MAPT (0.75) MAPTTP53KMT2AMEN1TRPV1
SCHEMBL1019967 0.75 SMN1; SMN2 (0.78) MAPTKMT2AMEN1TRPV1CASP3
SCHEMBL4111110 0.75 MAPT (0.75) MAPTTP53KMT2AMEN1TRPV1
SCHEMBL4915127 0.75 MAPT (0.75) MAPTTP53KMT2AMEN1TRPV1
SCHEMBL4920611 0.74 MAPT (0.73) MAPTKMT2AMEN1TRPV1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885TP53 4670/4885KMT2A 1905/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885TP53 4670/4885KMT2A 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.